Details for Patent: 8,569,347

Title:	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
Abstract:	Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Inventor(s):	Lee; Francis Y. F. (Yardley, PA)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:	May 20, 2004
Application Number:	10/850,072
Claims:	1. A method for treating lung cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula, ##STR00020## or a pharmaceutically-acceptable hydrate, solvate, or geometric, optical or stereoisomer of Compound (1), and a dosage unit of at least a second chemotherapeutic agent comprising antibody C225, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the antibody C225 alone. 2. The method of claim 1 wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment. 3. The method of claim 1 wherein the antibody C225 is administered following the administration of Compound (1). 4. The method according to claim 1, wherein the antibody C225 is administered before the administration of Compound (1). 5. The method according to claim 1, wherein the antibody C225 is administered substantially simultaneously with the administration of Compound (1). 6. The method according to claim 1, wherein the antibody C225 and the Compound (1) are both administered parenterally. 7. The method according to claim 1, wherein the cancer is non-small cell lung cancer. 8. A method for treating pancreatic cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula, ##STR00021## and/or a pharmaceutically-acceptable hydrate, solvate, and/or geometric, optical or stereoisomer of Compound (1), and a dosage unit of at least a second chemotherapeutic agent comprising antibody C225, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the antibody C225 alone. 9. The method of claim 8, wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment. 10. The method of claim 7, wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.